

UM/SBC147BUSA

**REMARKS/ARGUMENTS**

After entry of this paper, claims 2-7, 17, 18 and 21-29 are pending. Claims 1, 8-16 and 19-20 are canceled. These claims are canceled without prejudice, as being drawn to non-elected subject matter. Applicants reserve the right to prosecute the non-elected claims 8-15, 19-20 and subject matter removed from claims 1-7 and 16-18 in a divisional application filed during the pendency of the present application.

Pending claims 2-7, 17 and 18 are amended to clarify the invention, to remove non-elected subject matter, and to correct clerical errors. New claim 21 is supported by original claim 1. New claims 25-29 are supported by original claim 16. New claims 22-24 as well as the amendments in the other pending claims are supported in the original specification and claims and particularly at page 13, lines 15-18; page 15, lines 5-6 and 14-16; page 22, lines 25-27; page 20, line 24-page 21, line 4, and page 37 lines 13-19. No new matter is added by these amendments.

**Restriction Requirement**

*The Examiner restricted the claims into four (4) groups and required that Applicants elect the claims of one (1) group.*

In response to the outstanding requirement, Applicants have elected the claims of Group II, i.e., claims 1-7 and 16-18 drawn to a composition comprising a homolog or fragment of a polypeptide of SEQ ID NO: 4, without prejudice.

UM/SBC147BUSA

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9200  
Telefacsimile: (215) 540-5818